1. EASL Clinical Practice Guidelines: Management of chronic hepatitis B
European Association for the Study of the Liver 
Journal of Hepatology 
Volume 50, Issue 2, Pages (February 2009)
DOI: /j.jhep
Copyright © Terms and Conditions

2. Fig. 1
Rates of HBe seroconversion, undetectable HBV DNA and normal ALT at one year of therapy with pegylated interferon alpha-2a (PEG-IFN), lamivudine (LAM), adefovir (ADV), entecavir (ETV), telbivudine (LdT) and tenofovir (TDF) in HBeAg-positive patients with CHB in randomized clinical trials. These trials used different HBV DNA assays and they were not head-to-head comparisons for all the drugs; thus, these numbers are only indicative and should be considered with caution.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © Terms and Conditions

3. Fig. 2
Rates of undetectable HBV DNA and normal ALT at one year of therapy with pegylated interferon alpha-2a (PEG-IFN), lamivudine (LAM), adefovir (ADV), entecavir (ETV), telbivudine (LdT) and tenofovir (TDF) in HBeAg-negative patients with CHB in randomized clinical trials. These trials used different HBV DNA assays and they were not head-to-head comparisons for all the drugs; thus, these numbers are only indicative and should be considered with caution.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © Terms and Conditions

4. Fig. 3
Cumulative incidence of HBV resistance to lamivudine (LAM), adefovir (ADV), entecavir (ETV), telbivudine (LdT) and tenofovir (TDF) in published pivotal trials in NUC-naive patients. For method of calculation, see ref. [29]. These trials included different populations, used different exclusion criteria and different follow-up endpoints.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © Terms and Conditions